ה-FDA מאשר את הטיפול החודשי של טבע לסכיזופרניה

הערכה

The approval shifts schizophrenia care toward long-acting injectables, directly addressing the daily pill adherence problem that fuels relapse. For Teva, it adds a rare growth asset at a time when patients and prescribers increasingly prioritize convenience. Watch whether payers place the drug on restrictive tiers and how it competes with established rivals in the same monthly dosing space.